Aquestive Therapeutics, Inc. (AQST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 10M 20M 30M Q1 '17: 16.4M Q2 '17: 11.1M Q3 '17: 27.1M Q4 '17: 12.2M Q1 '18: 23.4M Q2 '18: 13.9M Q3 '18: 13.3M Q4 '18: 16.8M Q1 '19: 12.6M Q2 '19: 11.1M Q3 '19: 12.4M Q4 '19: 16.4M Q1 '20: 8.8M Q2 '20: 21.7M Q3 '20: 8.3M Q4 '20: 7.1M Q1 '21: 11.1M Q2 '21: 15.3M Q3 '21: 13.3M Q4 '21: 11.1M Q1 '22: 12.3M Q2 '22: 13.3M Q3 '22: 11.5M Q4 '22: 10.7M Q1 '23: 11.1M Q2 '23: 13.2M Q3 '23: 13M Q4 '23: 13.2M Q1 '24: 12.1M Q2 '24: 20.1M Q3 '24: 13.5M Q4 '24: 11.9M Q1 '25: 8.7M Q2 '25: 10M Q3 '25: 12.8M Q4 '25: 13M Q1 '26: 14.4M Q2 '26: 13.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 7M 14M 21M Q1 '19: 9.1M Q2 '19: 5.7M Q3 '19: 7.8M Q4 '19: 9.6M Q1 '20: 5.1M Q2 '20: 18.1M Q3 '20: 5.3M Q4 '20: 4.4M Q1 '21: 8.4M Q2 '21: 10.9M Q3 '21: 8.9M Q1 '22: 8.1M Q2 '22: 8M Q3 '22: 6.8M Q4 '22: 5.4M Q1 '23: 6.4M Q2 '23: 6.6M Q3 '23: 8.2M Q4 '23: 8.5M Q1 '24: 7.7M Q2 '24: 15.6M Q3 '24: 9.1M Q4 '24: 7.3M Q1 '25: 5.1M Q2 '25: 5.4M Q3 '25: 8.3M Q4 '25: 7.2M Q1 '26: 11M Q2 '26: 9.8M Q1 '19 Q1 '20 Q1 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q2 '17: -4.1M Q3 '17: 10.4M Q1 '18: 5.3M Q2 '18: -32.7M Q3 '18: -9.2M Q4 '18: -12.4M Q1 '19: -13.1M Q2 '19: -18.7M Q3 '19: -11M Q4 '19: -9.9M Q1 '20: -13.9M Q2 '20: 395K Q3 '20: -13.8M Q4 '20: -15.6M Q1 '21: -8.5M Q2 '21: -6.5M Q3 '21: -8M Q4 '21: -11.7M Q1 '22: -9.7M Q2 '22: -12.8M Q3 '22: -8.9M Q4 '22: -10.7M Q1 '23: -4.6M Q2 '23: -4.2M Q3 '23: -2.4M Q4 '23: -3.9M Q1 '24: -9M Q2 '24: 55K Q3 '24: -8.3M Q4 '24: -13.6M Q1 '25: -19.4M Q2 '25: -11.4M Q3 '25: -11.5M Q4 '25: -28.8M Q1 '26: -4.2M Q2 '26: -8.2M Q2 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '17: -1.5M Q2 '17: -5.9M Q3 '17: 8.5M Q4 '17: -10M Q1 '18: 4.1M Q2 '18: -36.5M Q3 '18: -15M Q4 '18: -13.9M Q1 '19: -14.7M Q2 '19: -20.5M Q3 '19: -18.4M Q4 '19: -12.6M Q1 '20: -16.5M Q2 '20: -2.3M Q3 '20: -16.6M Q4 '20: -20.4M Q1 '21: -14.7M Q2 '21: -12.4M Q3 '21: -14.6M Q4 '21: -28.9M Q1 '22: -13.2M Q2 '22: -16.3M Q3 '22: -12.5M Q4 '22: -12.4M Q1 '23: 8.1M Q2 '23: -5.8M Q3 '23: -2M Q4 '23: -8.1M Q1 '24: -12.8M Q2 '24: -2.7M Q3 '24: -11.5M Q4 '24: -17.1M Q1 '25: -22.9M Q2 '25: -13.5M Q3 '25: -15.4M Q4 '25: -31.9M Q1 '26: -8.1M Q2 '26: -22.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 2.5M 5M 7.5M Q1 '19: 3.5M Q2 '19: 5.4M Q3 '19: 4.6M Q4 '19: 6.8M Q1 '20: 3.7M Q2 '20: 3.5M Q3 '20: 3M Q4 '20: 2.8M Q1 '21: 2.8M Q2 '21: 4.5M Q3 '21: 4.4M Q1 '22: 4.2M Q2 '22: 5.2M Q3 '22: 4.6M Q4 '22: 5.3M Q1 '23: 4.7M Q2 '23: 6.6M Q3 '23: 4.8M Q4 '23: 4.7M Q1 '24: 4.4M Q2 '24: 4.5M Q3 '24: 4.4M Q4 '24: 4.5M Q1 '25: 3.7M Q2 '25: 4.6M Q3 '25: 4.5M Q4 '25: 5.8M Q1 '26: 3.5M Q2 '26: 4M Q1 '19 Q1 '20 Q1 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '17: 15.6M Q1 '18: 785K Q2 '18: 511K Q3 '18: -11.5M Q4 '18: -2.8M Q1 '19: -17.7M Q2 '19: -17.2M Q3 '19: -14.8M Q4 '19: -10.6M Q1 '20: -13.6M Q2 '20: -10M Q3 '20: -8.3M Q4 '20: -13.5M Q1 '21: -14.1M Q2 '21: -1.8M Q3 '21: -9.1M Q4 '21: -8.1M Q1 '22: -14.5M Q2 '22: -6.6M Q3 '22: 2.8M Q4 '22: 8.4M Q1 '23: 8.8M Q2 '23: -7.9M Q3 '23: -2.3M Q4 '23: -4.9M Q1 '24: -10.4M Q2 '24: -7M Q3 '24: -11.9M Q4 '24: -6.5M Q1 '25: -23.4M Q2 '25: -7.9M Q3 '25: -12.6M Q4 '25: -8.5M Q1 '26: -14.8M Q2 '26: -9.4M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '17: 15.2M Q1 '18: 526K Q2 '18: -116K Q3 '18: -11.9M Q4 '18: -3.3M Q1 '19: -18.1M Q2 '19: -17.3M Q3 '19: -14.9M Q4 '19: -10.7M Q1 '20: -13.8M Q2 '20: -10.1M Q3 '20: -8.4M Q4 '20: -13.7M Q1 '21: -14.2M Q2 '21: -1.9M Q3 '21: -9.1M Q4 '21: -8.6M Q1 '22: -14.6M Q2 '22: -7.2M Q3 '22: 2.6M Q4 '22: 8.4M Q1 '23: 8.8M Q2 '23: -8.7M Q3 '23: -2.5M Q4 '23: -5M Q1 '24: -10.4M Q2 '24: -7M Q3 '24: -12M Q4 '24: -6.5M Q1 '25: -23.5M Q2 '25: -8M Q3 '25: -12.9M Q4 '25: -8.6M Q1 '26: -14.9M Q2 '26: -9.7M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '18: 19.2M Q3 '18: 23.6M Q2 '19: 25M Q3 '19: 25M Q1 '20: 33.6M Q3 '20: 33.6M Q1 '21: 35.6M Q2 '21: 37.1M Q3 '21: 39.2M Q1 '22: 41.5M Q2 '22: 45.5M Q3 '22: 53.4M Q1 '23: 73.8M Q2 '23: 57.4M Q3 '23: 64.7M Q1 '24: 73.6M Q2 '24: 90.9M Q3 '24: 91.1M Q1 '25: 95.5M Q2 '25: 99.3M Q3 '25: 110.6M Q1 '26: 122.6M Q2 '26: 125M Q3 '18 Q1 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '18: -2.83 Q1 '19: -3.69 Q2 '19: -2.61 Q3 '19: -2.71 Q4 '19: -2.63 Q1 '20: -2.53 Q2 '20: -1.78 Q3 '20: -1.53 Q4 '20: -1.66 Q1 '21: -1.58 Q2 '21: -1.84 Q3 '21: -1.72 Q4 '21: -1.84 Q1 '22: -1.75 Q2 '22: -1.78 Q3 '22: -1.64 Q4 '22: -1.13 Q1 '23: -0.70 Q2 '23: -0.44 Q3 '23: -0.24 Q4 '23: -0.15 Q1 '24: -0.43 Q2 '24: -0.36 Q3 '24: -0.46 Q4 '24: -0.52 Q1 '25: -0.59 Q2 '25: -0.70 Q3 '25: -0.71 Q4 '25: -0.79 Q1 '26: -0.62 Q2 '26: -0.66 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.